XellSmart is a biotechnology company dedicated to developing scalable, low-cost, allogeneic stem cell therapies derived from induced pluripotent stem cells (iPSCs) to treat major degenerative diseases with high unmet medical need—such as ALS and Parkinson’s disease. With in-house GMP manufacturing, a state-of-the-art R&D center, and FDA-recognized clinical programs, we are transforming cutting-edge science into accessible, off-the-shelf regenerative solutions.
This page is dedicated to sharing our journey, achievements, and breakthroughs as we work to reshape the future of neurological care.
Company Details
- Founded
- -
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Keywords
- Founded in 2021.
Xellsmart Bio Questions
Xellsmart Bio's LinkedIn profile is https://www.linkedin.com/company/xellsmartbio
Xellsmart Bio's industry is
Research Services
Xellsmart Bio's top competitors are
Poltreg S.a.,
Hemogenyx Pharmaceuticals,
Tenaya Therapeutics,
Immuthera,
Estrella Biopharma, Inc,
Virocell Biologics,
Avencell,
Veongen Therapeutics Gmbh,
Maxcyte, Inc.,
Be Biopharma.
Xellsmart Bio's categories are Research Services
Xellsmart Bio's founding year is 2021
